ABSTRACT
reportedly reading CMI, 35% indicated concerns after reading. Factors associated with reading 26 included gender, type of CMI received and frequency of provision. 27
Conclusion: Consumers want and read information about their medicines, especially when 28 received from their GP or pharmacist. Healthcare professionals report usually discussing CMI 29 when providing it to patients, although continued improvements in dissemination rates are 30 desirable. Regular use of CMI remains a challenge, and ongoing strategies to promote CMI use 31 are necessary to improve uptake of CMI in Australia. 32
INTRODUCTION

36
Written medicine information is an important source of information for consumers and an 37 integral component of their education about medicines 1 . The literature contains evidence of its 38 role and value 2 , and positive impact on medicine knowledge, satisfaction and health literacy 3 . 39
Studies have focused on improving usability 4 and design 5 of written medicine information, 40 advocating consumer input into the evaluation process to enhance its usefulness to end-users. 41
Several factors have been shown to influence consumer evaluation and intended use of written 42 medicine information, notably health literacy, comprehension and perceived usefulness, which 43 can impact its benefits in practice 6 . 44
45
Consumers want written medicine information in conjunction with spoken information, 46 however many do not actively seek it 7, 8 . Self-report studies have indicated that healthcare 47 professionals regularly provide both oral and written information 9 , but this is generally not 48 reflected in consumer studies that report lower provision rates 9, 10 . General practitioners (GPs) 49 and pharmacists are considered the most important, trusted and reliable sources of written 50 medicine information 11 . However, despite growing evidence surrounding consumer desire and 51 interest in receiving written medicine information, healthcare professionals in Australia often 52 fail to provide it, and if provided, do so with limited interaction 12 . 53
54
In Australia, Consumer Medicine Information (CMI) is a standardized form of brand-specific 55 written medicine information produced by manufacturers according to strict legislation 13 , 56 essentially with limited consumer input (unlike the European Union). This has lead to 57 questions of sufficient independence of information, concerns regarding reliability and 58 credibility, and perceptions of a dominant medico-legal theme within CMI. 14 CMI for 59 prescription medicines is available electronically through dispensing or prescribing programs; 60 7
139
Questionnaires 140
141
The study questionnaires 27 were developed from earlier research 14 , and previous findings 15, 28 . 142 A central structured questionnaire was developed and subsequently adapted for each of the 143 three groups: consumer, GP and pharmacist. The questionnaires consisted of 7 sections: 144 knowledge of CMI (Section A); current use of CMI in practice (B); experience after provision of 145 CMI (C); opinions on the future provision of CMI (D); opinions on content and format of CMI 146 (E); improving provision and use of CMI (F); and demographic characteristics. The survey 147 contained primarily closed-ended questions with single or multiple response options, with an 148 'other' category included where suitable. This paper reports results relating to sections A, B 149 and C. Two panels consisting of pharmacists (n=8), consumer representatives (n=2) and other 150 experts in the field (n=9) reviewed all questionnaires for content and face validity. 151
Questionnaires were then piloted with four pharmacists (postal) and twenty-five consumers 152 (telephone). Any changes derived from feedback were reflected across all three questionnaires. 153
154
Data Analysis 155 156
All data were coded and entered into the Statistical Package for Social Sciences (Version 19.0 157 IBM). Not all questions were answered and/or some allowed multiple responses hence the 158 number of respondents varied for each question. Descriptive and frequency distributions were 159 compiled for all categorical values for each group. To determine the relationship between 160 variables, univariate analyses were conducted using non-parametric Chi-squared or Mann 161 Whitney U tests for each group and to compare differences between pharmacists and GPs. 162
Variables that were significant at p<0.25 29 were included as predictors for logistic regression to 163 predict readership and provision. As exploratory analysis was conducted with no priorassumptions, logistic regression was performed using the forced entry method (all predictors 165 entered into the equation simultaneously). 29 Of the consumers, almost half (n=474, 47%) were aware of CMI (for prescription medicines), 201 with a further 207 (20%) reporting knowledge about medicine leaflets but not as CMI. In 202 contrast, 99% (n=344) of pharmacists and 90% (n=162) of GPs were aware of CMI. Those 203 consumers reporting they were aware of CMI, cited pharmacists, doctors or package inserts as 204 common sources (Table 1) . GP and pharmacist respondents indicated similar results, however, 205 pharmacists did not report the doctor as a source of CMI as frequently as GPs and consumers. 206
More GP and pharmacist respondents reported the Internet as a source of CMI than consumers, 207 highlighting a lack of awareness of this source amongst consumers. 208
209
Most consumers (n=691, 69%) reported receiving CMI for their prescription medicine in the 6 210 months prior to their survey; supplied either by a pharmacist (n=267, 39%), doctor (n=124, 211 18%), pharmacy assistant (n=33, 5%), family member/carer (n=10, 1%) or found as a package 212 insert (n=366, 53%). Almost half (n=327, 47%) reported receiving CMI every time they 213 received a new medicine, whilst 272 (40%) received it when collecting a repeat prescription for a 214 regular medicine. Ten percent (n=69) received it only when they asked for it.
There was disparity amongst the types of written medicine received or provided. Over three-217 quarters of pharmacists (n=272, 78%) and less than half of GPs (n=87, 48%) reported providing 218 package inserts, yet most consumers (n=606, 88%) reported receiving them when provided with 219 written medicine information. Computer generated CMI was commonly provided by 220 pharmacists (n=347, 99%) and GPs (n=101, 56%), however this was not reflected in consumer 221 responses that reported only 37% (n=257) receiving computer-generated CMI. Forty percent 222 (n=141) of pharmacists and 25% of GPs (n=45) All pharmacists (n=1 missing data) and 69% (n=125) of GPs reported providing CMI. 251
Pharmacists reported providing CMI when dispensing a new medicine most (n=150, 43%) or all 252 (n=168, 48%) of the time, and provided CMI with repeat medicines some (n=244, 70%) or none 253 (n=101, 29%) of the time. Similarly, GPs provided CMI most (n=56, 31%) or all (n=18, 10%) of 254 the time with new medicines, and some (n=53, 29%) or none (n=123, 68%) of the time with 255 repeat prescribing. On the availability of new information about a medicine, GPs provided CMI 256 most (n=53, 17%) or all (n=94, 52%) of the time in comparison to pharmacists (n=112, 32% and 257 n=73, 21%, respectively). 258
259
Logistic regression was performed to determine healthcare professional variables that impact 260 provision of CMI (Table 3b) . Pharmacist data could not be included in analysis as these 261 respondents all reported providing CMI, therefore regression was conducted using GP 262 respondent variables. The model contained nine independent variables relating to gender, type 263 of CMI provided, source of CMI and access to CMI. The final model was statistically significant 264 2 (9, n=179) = 127.83, p<0.001, and performed well in distinguishing GPs who reported 265 providing CMI or not. Overall, the model successfully predicted 89.4% of the cases. Wald 266 statistics (Table 3b) showed type, source and access to CMI reliably predicted GPs who 267 provided CMI. GPs who used computer-generated CMI and relied on package inserts insample boxes were more likely to provide CMI. Similarly, those GPs with access to prescribing 269 software and pharmaceutical company websites were also far more likely to provide CMI. 270
Finally, GPs that reported themselves as the patient access point for CMI were almost eight 271 times more likely to provide CMI. 272
273
The reported reasons for providing or NOT providing CMI (Table 4 ) by pharmacists and GPs 274 varied. Pharmacists' were more likely to provide CMI, apart from on patient request, 275 predominantly because of patients' right to information, informed choice, reinforcing medicine-276 taking behaviour and verifying their own knowledge, than GPs. This differed significantly 277 from GPs whose reasons were mostly associated with requests by patients for CMI. 278
279
Pharmacists' were more likely NOT to provide CMI (Table 4) due to the reasons of knowing 280 that patients had taken the medicine previously; or concerns with patients' difficulty in 281 understanding/reading CMI, patient non-adherence and use of the medicine off-label, when 282 compared to GPs. However, GPs reported NOT providing CMI (Table 4) predominantly 283 because patients received sufficient spoken information from them and they experienced a lack 284 of time with patients. Interestingly, GPs also did not provide CMI because they believed the 285 patient would receive this information from their pharmacist. 286
287
CMI in practice 288 289
Mann-Whitney U testing revealed few differences in the use of CMI in patient 290 interactions/consultations between GPs and pharmacists ( Table 5 ). The majority of 291 pharmacists and GPs reported verbally discussing sections of the CMI with patients or drew 292 their attention to sections of the CMI, although pharmacists were more likely to do so most to 293 all of the time in comparison to GPs who reported doing so some to most of the time. Most 294 pharmacists or GPs were unlikely to provide CMI without verbal counseling, but few discussedthe entire CMI with their patients. Various sections of the CMI were discussed with patients 296 (Table 2) . Side effects were the most discussed section, followed by what the medicine is for. 297
298
Three-hundred and eighteen consumers reported directly receiving CMI from their pharmacist 299 or GP; 108 (34%) reported CMI being given to them with no further discussion, and a similar 300 proportion (n=93; 29%) had a CMI discussed in detail with them. Others (n=57, 18%) had 301 sections pointed out to them and 45 (14%) were provided CMI, asked to read and return if they 302 had questions. 303 304
Concerns and queries 305 306
Of the 457 consumers who reported reading CMI, 164 (35%) reported a concern or query after 307 reading; the predominant being experiencing a side effect (n=101, 62%), drug-drug interactions 308 (n=43, 26%) and needing more information and/or instructions about the medicine (n=24, 15%). 309
Most pharmacists (n=320, 92%) and GPs (n=161, 89%) reported that their patients had 310 concerns or queries after reading CMI. Consumers' initial action was to contact the doctor 311 (n=98, 60%), followed by the pharmacist (n=51, 31%) with 5% (n=8) refusing to take the 312 medicine. Pharmacists and GPs reported the reverse, indicating pharmacists being the first 313 contact (reported by 315 or 90% of pharmacists; and 145 or 81% of GPs), followed by the GP 314 (n=135, 39% pharmacists; n=97, 54% GPs). Over two-thirds of GPs (n=112, 62%) and about a 315 quarter of pharmacists (n=95, 27%) reported patients refusing/ceasing to take their medicine. 316
Following on from the initial action and after consulting with the doctor or pharmacist, over 317 half of consumers (n=73, 55%), pharmacists (n=156, 58%) and GPs (n=81, 57%) reported no 318 change in the patients' medicine. The other half reported changing the medicine (n=21, 16% 319 consumers; n=39, 14% pharmacists; n=14, 10% GPs), ceasing the medicine (n=19, 14% 320 consumers; n=19, 7% pharmacists; n=19, 13% GPs), changing dosages (n=17, 13% consumers;n=5, 2% pharmacists; n=1, 1% GPs) or providing reassurance, further clarification/explanation 322 (n=18, 14% consumers; n=26, 10% pharmacists; n=23, 16% GPs). 323
324
DISCUSSION
326
This study compared consumers', pharmacists' and GPs' awareness, use and provision of CMI, 327 and identified some factors associated with its readership and provision. A representative 328 consumer sample was achieved for demographic distribution through recruiting according to 329 geographic stratification quotas, with proportional representation per State and Territory, and 330 metropolitan and rural populations. In terms of gender the study contained 52% females, 331 similar to the desired sampling frame of 52.5% females. The median age for consumer 332 participants was 60 years in comparison to 37 years for the Australian population. 30 As the 333 study specifically targeted medicine users the higher median age of participants is not 334 unexpected as medication use and proportion of medicines used increases with age. Of note, 335 consumer respondents' education levels varied significantly, particularly the percentage of 336 participants who held tertiary qualifications was much higher than ABS 31 reported data (37% vs 337 23%) which may have influenced consumers use of CMI. 338
339
The results showed that over two-thirds of consumers were aware of written medicine 340 information, predominantly as CMI, an encouraging improvement from previous studies 10, 15 computer-generated CMI compared to package inserts, however whether they actively 360 distribute the package insert or assume its presence is unclear. 361
362
Patients often prefer to receive medicine information from their doctor, however time 363 restrictions may limit a doctor's ability to provide this 35 , which was mirrored in over a third of 364 GP respondents reporting insufficient time to spend with the patient on providing CMI 365 compared to less than one-tenth of pharmacists. This may explain the study results showing 366 pharmacists as the predominant source of CMI for consumers (88% vs 70% for GPs); perhaps 367 seen as 'medicine experts', readily accessible, able to fill information gaps post-consultation 368 (with potential to alleviate time burdens on GPs); and they are often the final healthcare 369 professional patients consult before taking their medicine 36, 37 . GPs too, predominantly rely on 370 pharmacists to provide CMI and counseling 20 , see pharmacists as the primary source of CMI 371
and as such their belief may explain the lack of CMI provision in consultation, as highlighted inSimilar to previous studies, 66% of consumers in this study reported reading CMI, with females 375 twice as likely to read CMI as males 10, 38 . Readership may be influenced by the nature and 376 quality (design, flimsy nature and small font) of written medicine information (i.e. package 377 inserts) which in turn affects readability and usability by consumers. 39 Despite observations to 378 the contrary 14 , this study found negligible impact of quantity and length on consumer 379 readership of CMI. Consumer respondents were more likely to read medicine information 380 provided by their healthcare professional, compared to package inserts, substantiating the 381 influence of personally provided information on readership, and perception of its usefulness. 40 382
Previous findings indicate a positive association with physician counseling and reading written 383 medicine information. 37 Interestingly, computer-generated written medicine information other 384 than CMI strongly predicted consumer readership in this study, with consumers almost four 385 times more likely to read this information. It can only be speculated, since it was not elucidated, 386
that GPs' and pharmacists' personal preference and perceptions of other written medicine 387 information as more patient-focused, relevant, and readable to consumers than CMI may 388 influence the interaction and time afforded to consumers in disseminating this information, 389 providing a sense of tailoring or personalization that impacts consumer readership. Findings 390 from previous studies indicate patient preference is for written medicine information tailored to 391 the individual 41 and which highlights the medicine's benefits 42 . 392
393
Evidence shows consumers value face-to-face contact 43 . Two thirds of consumers reported a 394 range of interactions with the pharmacist or GP when being provided with CMI. In this study, 395
GPs and pharmacists were unlikely to provide CMI without verbal counseling, the downside of 396 which may mean consumers are missing out on receiving CMI if time is limited, which is often 397 the case in consultations. 14 However, if CMI is provided, the interaction or discussionhealthcare professionals in providing written and spoken information is a vital component in 400 maximizing the impact and importance of CMI, as well as assisting consumers to understand 401 the risks and benefits of their medicines 37, 44 . 402
403
Time limitations and imparting sufficient spoken information were significantly more likely to 404 be reasons for not providing CMI for GPs than pharmacist respondents. Short consultation 405 times, high workloads and limited resources contribute to the down-prioritisation of CMI in 406 consultations 20 . This, along with perceptions around role responsibility (as inferred in the 407 results as the preference for the pharmacist as a source of CMI) may further explain why often 408 only spoken information is provided by GPs. This study also found factors such as ready access 409 to CMI from prescribing software, pharmaceutical websites and sample packs significantly 410 influenced the provision of CMI, as did self-identification by GPs as a source of CMI for 411 patients predicting that GPs who self-identify as a source of CMI are almost eight times more 412 likely to provide it. Pharmacists were more likely to support providing CMI due to beliefs 413 surrounding consumers' rights to information, duty of care, and promoting informed choice 414 than GPs, although this was still notable among them. In Australia, the provision of medicines 415 information as a key role is reinforced by professional practice guidelines 45 , education 416 programs 23 and at practice level through remuneration linked to CMI provision. 417
418
Despite the welcome increases to provision rates and ongoing improvements to CMI over the 419 last decade, negative perceptions from healthcare professionals still persist. 20 The idea of 420 written medicine information must be compatible with GP and pharmacist needs, values and 421 experiences as well as that of consumers. Past negative experiences such as consumers declining 422 CMI when offered, concerns or failure to take medicines after reading CMI (which may be valid 423 and appropriate actions) may pose barriers and interfere with the successful adoption by GPs 424 and pharmacists of CMI in everyday practice. Many GPs (89%) and pharmacists (92%)reported situations where consumers had concerns or queries after reading CMI, resulting in 426 consumers refusing to take or ceasing their medicine, reflecting an earlier study with 427 physicians 46 . Notwithstanding these results and accounts in the literature of a relationship 428 between side effect fear and ceasing medication 47 , very few consumer respondents in this study 429 reported refusing to take or ceasing their prescribed medicine, possibly inferring a confidence in 430 their practitioners treatment decisions. Thus, this relatively low incidence does not support 431 GP and pharmacist perceptions, nor justify their reluctance to provide CMI to patients on this 432
basis. Concerns about understandability, usability and readability expressed by a significant 433 proportion of GPs and pharmacists may also contribute to the undervaluing of CMI as a tool for 434 information-sharing and further contribute to non-provision of CMI to consumers. Despite 435 these concerns and some negative perceptions of the value of CMI held by healthcare 436 professionals, consumers find CMI useful, informative and educational and as such should at 437 each opportunity be at the very least offered the option of receiving a CMI. 38,48 438
439
Limitations to this research must be considered when interpreting the results. The response 440 rates may indicate a bias towards participants with a specific interest in CMI. The results have 441 been derived from self-report data, and subject to personal, social desirability and/or recall bias. 442
However, a representative consumer sample was achieved with regard to gender and location in 443 accordance with ABS data. Data was not collected on the medicines consumers were currently 444 taking and the influence this may have had on their responses. Consumers may receive written 445 medicine information for various medicines and illnesses, and it is possible that their perception 446 and readership of the leaflets may have been influenced by the seriousness or chronic nature of 447 their treatment. Consideration should also be given to the limitations of telephone surveys 448 despite the advantages of rapid data collection and accessibility to respondents. Inattentiveness, 449
time constraints or open-ended questions may negatively affect participant responses.calls were limited to unrestricted landlines. Due to increases in telemarketing, many 452 households employ call screening and thus may have opted not to answer the telephone. GP 453 response rates were lower than expected, despite follow-up, which may reflect the low priority 454 that CMI has for invitees. The GPs' and pharmacists' respondent sample whilst not 455 generalisable, may provide constructive insight into the use and provision practices of GPs and 456 pharmacists in relation to CMI, providing a basis from which to direct further research. 457
458
CONCLUSION
460
The awareness of CMI among consumers, community pharmacists and GPs has increased in 461
Australia over the past decade, along with the proportion of consumers receiving CMI. 462
However, provision rates remain lower than desirable, implying that the value of CMI has not 463 been fully realized or accepted by healthcare professionals, despite improvements in access, 464 development and quality of CMI, associated education programs and professional guidelines. 465
Although CMI may not be the best source of medicine information for all consumers, it is 466 currently the most comprehensive written information available for all prescription medicines 467 in Australia. At a minimum all consumers should at least be offered CMI in consultation, 468 providing healthcare professionals with the opportunity to engage consumers and determine 469 their beliefs, expectations and needs surrounding the amount and type of information desired. 
14.
Hamrosi KK, Aslani P, Raynor DK. Beyond needs and expectations: identifying the 523 barriers and facilitators to written medicine information provision and use in Australia. 524
Health Expect. Mar 6 2012. 525
15.
Benton M, Snow K, Parr V.
Evaluation of the Medicines Information for Consumer (MIC) 526
Program: Pharmacy Guild of Australia;2004. 527
16.
Vitry 
20.
Hamrosi KK, Raynor DK, Aslani P. Pharmacist and general practitioner ambivalence 537 about providing written medicine information to patients-A qualitative study.
Res Social 538
Adm Pharm. Sep-Oct 2013;9(5):517-530. 539
21.
Kalton G. 
23.
Aslani 
29.
Hosmer DK, Lemeshow S. 
34.
Raynor 
39.
Moorthi C, Saravanakumar RT, Senthil Kumar C, Manavalan R, Kathiresan K. 593
Systematic assessment of the quality of patient information leaflets supplied by the 594 pharmaceutical manufacturers. Pharmacie Globale. 2012;3(2):1-3. 595
40.
Raynor DK, Knapp P. Do patients see, read and retain the new mandatory medicines 596 information leaflets ? Pharm J. 2000; 264:268-270 . 597
41.
Dickinson R, Hamrosi K, Knapp P, et al. Suits you? A qualitative study exploring 598 preferences regarding the tailoring of consumer medicines information. Int J Pharm 599
Pract. Nov 13 2012. 600
42.
Hamrosi K, Dickinson R, Knapp P, et al. It's for your benefit: exploring patients' 601 opinions about the inclusion of textual and numerical benefit information in medicine 602 leaflets. Int J Pharm Pract. Nov 9 2012. 603
43.
Raynor DK, Savage I, Knapp P, Henley J. 
